Gilbert changed his life with Vida
Member Story
Resources
-
The cost of discontinued care: Why GLP-1 coverage fails without clinical continuity
If your organization’s cardiometabolic health strategy begins and ends with GLP-1 coverage, you don’t really have a strategy. You have a pharmacy decision masquerading as population health.
-
What Employers need to know before dropping GLP-1 coverage
Now more than ever employers and plan sponsors are considering altering or removing GLP-1 coverage, but short-term cost cuts can quickly become long term expenses. This guide can help you make a strategic informed decision whether you decide keep GLP-1s on formulary or not.
-
Clinicians or Technology? What we should be asking instead.
This crisis in accessibility has laid the foundation for an unproductive debate: should we rely more heavily on clinicians, or tech and AI? But that’s the wrong argument. The real question is whether care models deliver measurable, durable outcomes, beyond who or what is providing that care.